NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.70 -0.10 (-0.13%) GOLD FUTURES
2,433.60 -4.90 (-0.20%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,929.09 +2,699.80 (+5.17%)
LH Nov 2024 175.000 put
| Previous close | 3.1000 |
| Open | 3.1000 |
| Bid | 0.5500 |
| Ask | 2.7000 |
| Strike | 175.00 |
| Expiry date | 2024-11-15 |
| Day's range | 3.1000 - 3.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
GuruFocus.comInsider Sale: EVP, Chief Legal Officer van der Vaart Sandra D Sells Shares of Laboratory Corp ...
On May 14, 2024, van der Vaart Sandra D, Executive Vice President and Chief Legal Officer, sold 2,000 shares of Laboratory Corp of America Holdings (NYSE:LH) as reported in a recent SEC Filing.
ZacksLabcorp (LH) to Assess Preeclampsia Risk With New Test
Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
PR NewswireLabcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of pregnancy. It is the only test of its kind available in the United States and is relevant for all pregnant individuals, including those with a low- to average-risk for preeclampsia or first-time pregnancies.
